These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26935359)

  • 1. Antihypertensive Efficacy of the Direct Renin Inhibitor Aliskiren as Add-on Therapy in Patients with Poorly Controlled Hypertension.
    Tani S; Kushiro T; Takahashi A; Kawamata H; Ohkubo K; Nagao K; Hirayama A
    Intern Med; 2016; 55(5):427-35. PubMed ID: 26935359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Add-on aliskiren treatment can decrease blood pressure but requires attention to risks of renal impairment and hyperkalemia Chikushi Anti-Hypertension Trial-Rasilez® (CHAT-Ras).
    Okamura K; Takamiya Y; Mori K; Shirai K; Urata H
    Clin Exp Hypertens; 2020 Aug; 42(6):545-552. PubMed ID: 32037898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct renin inhibition: focus on aliskiren.
    Pool JL
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):21-33. PubMed ID: 17970614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
    Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
    Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
    J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a future for direct renin inhibitors?
    Chaudhary K; Nistala R; Whaley-Connell A
    Expert Opin Investig Drugs; 2010 May; 19(5):653-61. PubMed ID: 20380486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical role of direct renin inhibition in hypertension.
    Taylor AA; Pool JL
    Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
    Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
    Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development.
    Jadhav M; Yeola C; Zope G; Nabar A
    J Postgrad Med; 2012; 58(1):32-8. PubMed ID: 22387646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS).
    Volman S; Benitez FN; Cedenio H; Giorgi M; Jaramillo N; Molina N; Zilberman J
    Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):189-96. PubMed ID: 23723254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
    Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Smith B; Weissbach N; Maboudian M; Botha J; van Ingen H
    Circulation; 2009 Jan; 119(3):417-25. PubMed ID: 19139391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease.
    Li SY; Chen YT; Yang WC; Tarng DC; Lin CC; Yang CY; Liu WS
    BMC Nephrol; 2012 Aug; 13():89. PubMed ID: 22917002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.
    Rashikh A; Ahmad SJ; Pillai KK; Najmi AK
    J Pharm Pharmacol; 2012 Apr; 64(4):470-81. PubMed ID: 22420653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.